-
Mesothelioma update - New drug trial
-
The M. D. Cancer Centre at the University of Texas is at the centre of clinical trials involving a new drug called Dastanib to try to reduce and prevent the progression of mesothelioma.
Dastanib may be useful for those mesothelioma patients who are not responding to other available therapies or those who are unable to consume some drugs due to allergic reactions or side effects.
A dedicated team of doctors have been assigned specific roles for the better treatment of the patients involved in the trials. The team is based on experts in thoracic medical oncology, radiation and pulmonary and pathological fields.
Mesothelioma is a form of cancer that is almost always caused by exposure to asbestos. In this disease, malignant cells develop in the mesothelium, a protective lining that covers most of the body's internal organs. Its most common site is the pleura outer lining of the lungs and internal chest wall but it may also occur in the lining of the abdominal cavity or the heart.
Most people who develop mesothelioma have worked on jobs where they inhaled asbestos particles, or they have been exposed to asbestos dust and fibre in other ways. It can also occur when family members of those who worked with asbestos have come into contact with asbestos when washing their clothes.
Treatment for mesothelioma depends on the location of the cancer, the stage of the disease, and the patient's age and general health. Standard treatment options include surgery, radiation therapy, and chemotherapy. Sometimes, these treatments are combined.
Simpson Millar’s team of highly skilled industrial disease lawyers have experience of dealing with claims for mesothelioma. If you or a member of your family have been diagnosed with mesothelioma please contact us to find out if you could be entitled to compensation by calling freephone: 0800 634 1632 or send us your enquiry via email using our online form and we will get in touch with you.
Useful info:
This article was written by Maeve McCusker, Occupational Illness Team.
-
Emma Costin
-
12/10/2009
Disclaimer: No information on this website shall be construed as
legal advice and information is offered for general information purposes only based on the current law when the information was first displayed on this website. You should
always seek advice from an appropriately qualified solicitor on any specific legal
enquiry. Calls to or from our legal helpline may be recorded for training and monitoring purposes.
External links are provided for your convenience, but they are beyond the control
of Simpson Millar LLP and no representation is made as to their content. Use or
reliance on any external links and the content thereon provided is at your own risk.
Full terms of use...